Overview
- Cash-paying patients now pay $299 per month for the 2.5 mg Zepbound vial, $399 for 5 mg, and $449 for 7.5–15 mg when purchased through LillyDirect’s Self Pay Journey Program.
- Lilly’s move follows Novo Nordisk’s November cuts that set Ozempic and Wegovy at $349 a month for cash buyers with a $199 introductory offer for the two lowest doses in the first two months.
- The latest reductions come after a November agreement with the Trump administration that targets TrumpRx cash prices of about $350 per month next year, trending to $245 over two years.
- Expanded Medicare and Medicaid savings are slated to begin in 2026, with Medicare copays as low as $50 for certain multi‑dose pens and Lilly’s oral orforglipron if the FDA grants approvals.
- Investors reacted with modest declines in the drugmakers’ shares as Lilly and Novo vie with each other and with lower-cost telehealth sellers in the fast-growing GLP‑1 market.